[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656559":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":19,"studyPopulation":19,"armGroups":29,"interventions":40,"overallOfficials":48,"centralContacts":52,"locations":61,"responsibleParty":75,"collaborators":19,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":19,"enrollmentInfo":87,"targetDuration":19,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":19,"overallStatus":98,"whyStopped":19,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":19},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with LG IR NMIBC with Complete Response","Complete response rate is defined as negative cystoscopy and negative cytology .","Baseline, 2 Years",{"measure":14,"description":15,"timeFrame":12},"Number of Participants with LG UTUC with Complete Response","Complete response rate is defined as negative uterorenoscopy or nephroscopy assessment and negative cytology, per investigator assessment.",[17,21],{"measure":18,"description":19,"timeFrame":20},"Duration of Response",null,"Baseline, 5 Years",{"measure":22,"description":19,"timeFrame":20},"Time to Recurrence",{"allocation":24,"interventionModel":25,"interventionModelDescription":19,"primaryPurpose":26,"observationalModel":19,"timePerspective":19,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":19,"whoMasked":19},"NONE",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"Cohort A: Vepugratinib","EXPERIMENTAL","Vepugratinib will be administered orally to participants with low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC)",[35],"Drug: Vepugratinib",{"label":37,"type":32,"description":38,"interventionNames":39},"Cohort B: Vepugratinib","Vepugratinib will be administered orally to participants with low-grade upper tract urothelial carcinoma (LG UTUC)",[35],[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"DRUG","Vepugratinib","Administered orally",[31,37],[47],"LY3866288",[49],{"name":50,"affiliation":5,"role":51},"1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":19,"email":57},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":59,"role":55,"phone":19,"phoneExt":19,"email":60},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[62],{"facility":63,"status":19,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":19},"Carolina Urologic Research Center","Myrtle Beach","South Carolina","29572","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-78.88669,33.68906,{"lat":73,"lon":72},{"type":76,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100656559","phase-2-a-study-of-vepugratinib-ly3866288-in-adults-with-non-muscle-invasive-bladder-cancer-and-upper-tract-urothelial-cancer-100656559",false,"NCT07827612","A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer","FORAY: A Phase 2, Randomized, Open-Label Study Evaluating Vepugratinib in Adults With FGFR3 Altered Low Grade, Intermediate Risk, Non-muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma","FORAY","Inclusion Criteria:\n\n* All Participants:\n\n  * Have a PS of 0 to 2 on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale\n* Cohort A\n\n  * Have histologically confirmed LG NMIBC.\n  * Have LG IR NMIBC at time of screening\n  * Have a documented qualifying fibroblast growth factor receptor 3 protein (FGFR3) mutation or fusion\n* Cohort B\n\n  * Have histologically confirmed LG UTUC.\n\nExclusion Criteria:\n\n* All Participants\n\n  * Have had a prior positive urine cytology within 6 weeks of first day of treatment.\n  * Have received prior local instillation (for example, intravesical chemotherapy, Bacillus Calmette-Guerin, Jelmyto) therapy within 8 weeks of the first day of treatment.\n* Cohort A\n\n  * Have synchronous UTUC disease.\n  * Have presence of, or history of, high-grade urothelial carcinoma within 3 years of the first day of treatment, or presence of, or history of, carcinoma in situ.\n* Cohort B\n\n  * Have presence of bladder tumors at the time of enrollment.\n  * Have presence of, or history of, high-grade urothelial carcinoma or carcinoma in situ.","ALL","18 Years",{"count":88,"type":89},161,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted.\n\nFor each participant, the study will last up to 5 years.",[95,96,97],"Urinary Bladder Neoplasms","Urologic Neoplasms","Receptor, Fibroblast Growth Factor, Type 3","NOT_YET_RECRUITING","2026-10-07",{"date":101,"type":102},"2026-10-08","ACTUAL",{"date":104,"type":89},"2026-12",{"date":106,"type":89},"2031-03",{"name":5,"class":6},1]